The pharmaceutical player's net loss narrowed to Rs 44.62 crore in the March 2022 quarter. The company reported a net loss of Rs 135.02 cro...

In the Nifty pack, 12 stocks were trading in the green, while 38 stocks were trading in the red.

After reporting a drop in revenue and a net loss for FY21, the company is expected to benefit from high potential new molecules that are cu...

Shares of Dishman Carbogen Amcis jumped 8 per cent up in early trade, after veteran investor Mukul Agrawal upped his stake in the company, ...

Dishman Carbogen Amcis Ltd., incorporated in the year 2007, is a Small Cap company (having a market cap of Rs 3280.69 Crore) operating in P...

Nirmal Bang has a ‘Buy’ call on Dishman Carbogen with a target price of Rs 185. Dishman Carbogen Amcis on Thursday said Income Tax Departme...

"The officials of Income-Tax Department conducted a search at the Company''s Offices and Manufacturing sites. Company has extended full co-...

Buy Dishman Carbogen Amcis at a price target of Rs 380.

Buy Dishman Carbogen Amcis Ltd. at a price target of Rs 355.

Buy Dishman Carbogen Amcis Ltd. at a price target of Rs 415.0 .

Buy Dishman Carbogen Amcis Ltd. at a price target of Rs 404.0 .

Following the announcement, the stock hit its upper circuit limit of 20 per cent at Rs 278.20 on BSE.

Drug firm Dishman Pharmaceuticals and Chemicals today said Mark Griffiths has been appointed as Chief Executive Officer of Dishman Group of...

Dishman Pharma and Chemicals today said its Switzerland-based subsidiary has acquired Creapharm Parenterals for an undisclosed amount.

Prabhudas Lilladher has reiterated ‘outperformer’ rating on Dishman Pharmaceuticals for a price target of Rs 449 (15x FY10 earnings), an im...

Revenues from the US will see a quantum jump to over 40% of consolidated sales of Dishman Pharmaceuticals & Chemicals this year from around...

Dishman Pharmaceuticals and Chemicals Ltd on Wednesday said it has acquired Swiss Research based company Cabbogen Amcis AG from Solutia Eur...